This Article Full Text Full Text (PDF) Supplemental Data File All Versions of this Article: 18/7/1599    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hillisch, A. Articles by Fritzemeier, K.-H. Search for Related Content PubMed PubMed Citation Articles by Hillisch, A. Articles by Fritzemeier, K.-H.

Dissecting Physiological Roles of Estrogen Receptor and ß with Potent Selective Ligands from Structure-Based Design

EnTec Gesellschaft für Endokrinologische Technologie GmbH (A.H., B.S., G.R., W.E.), and Jenapharm GmbH & Co. KG (O.P., D.K., G.M.), D-07745 Jena, Germany; and Schering AG (A.W., K.-H.F.), D-13342 Berlin, Germany

Address all correspondence and requests for reprints to: Dr. Karl-Heinrich Fritzemeier, Schering AG, Müllerstrasse 170–178, D-13342 Berlin, Germany. E-mail: karlheinrich.fritzemeier{at}schering.de.

The distinct roles of the two estrogen receptor (ER) isotypes, ER and ERß, in mediating the physiological responses to estrogens are not completely understood. Although knockout animal experiments have been aiding to gain insight into estrogen signaling, additional information on the function of ER and ERß will be provided by the application of isotype-selective ER agonists. Based on the crystal structure of the ER ligand binding domain and a homology model of the ERß-ligand binding domain, we have designed steroidal ligands that exploit the differences in size and flexibility of the two ligand binding cavities. Compounds predicted to bind preferentially to either ER or ERß were synthesized and tested in vitro using radio-ligand competition and transactivation assays. This approach directly led to highly ER isotype-selective (200-fold) and potent ligands. To unravel physiological roles of the two receptors, in vivo experiments with rats were conducted using the ER- and ERß-selective agonists in comparison to 17ß-estradiol. The ER agonist induced uterine growth, caused bone-protective effects, reduced LH and FSH plasma levels, and increased angiotensin I, whereas the ERß agonist did not at all or only at high doses lead to such effects, despite high plasma levels. It can thus be concluded that estrogen effects on the uterus, pituitary, bone, and liver are primarily mediated via ER. Simultaneous administration of the ER and ERß ligand did not lead to an attenuation of ER-mediated effects on the uterus, pituitary, and liver parameters.

NURSA Molecule Pages Link:

Nuclear Receptors:   ERα  |  ERβ  |  GR  |  MR  |  PR  |  AR

Ligands:   17β-Estradiol

This article has been cited by other articles:

				M. C. Catley, M. A. Birrell, E. L. Hardaker, J. de Alba, S. Farrow, S. Haj-Yahia, and M. G. Belvisi Estrogen Receptor {beta}: Expression Profile and Possible Anti-Inflammatory Role in Disease J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 83 - 88. [Abstract] [Full Text] [PDF]

				V. Jazbutyte, P. A. Arias-Loza, K. Hu, J. Widder, V. Govindaraj, C. von Poser-Klein, J. Bauersachs, K.-H. Fritzemeier, C. Hegele-Hartung, L. Neyses, et al. Ligand-dependent activation of ER{beta} lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats Cardiovasc Res, March 1, 2008; 77(4): 774 - 781. [Abstract] [Full Text] [PDF]

				J. A. Arreguin-Arevalo, T. L. Davis, and T. M. Nett Differential Modulation of Gonadotropin Secretion by Selective Estrogen Receptor 1 and Estrogen Receptor 2 Agonists in Ovariectomized Ewes Biol Reprod, August 1, 2007; 77(2): 320 - 328. [Abstract] [Full Text] [PDF]

				P.-A. Arias-Loza, K. Hu, C. Dienesch, A. M. Mehlich, S. Konig, V. Jazbutyte, L. Neyses, C. Hegele-Hartung, K. Heinrich Fritzemeier, and T. Pelzer Both Estrogen Receptor Subtypes, {alpha} and {beta}, Attenuate Cardiovascular Remodeling in Aldosterone Salt-Treated Rats Hypertension, August 1, 2007; 50(2): 432 - 438. [Abstract] [Full Text] [PDF]

				C. Glidewell-Kenney, L. A. Hurley, L. Pfaff, J. Weiss, J. E. Levine, and J. L. Jameson Nonclassical estrogen receptor {alpha} signaling mediates negative feedback in the female mouse reproductive axis PNAS, May 8, 2007; 104(19): 8173 - 8177. [Abstract] [Full Text] [PDF]

				S. J. McPherson, S. J. Ellem, E. R. Simpson, V. Patchev, K.-H. Fritzemeier, and G. P. Risbridger Essential Role for Estrogen Receptor {beta} in Stromal-Epithelial Regulation of Prostatic Hyperplasia Endocrinology, February 1, 2007; 148(2): 566 - 574. [Abstract] [Full Text] [PDF]

				H. A. Harris Estrogen Receptor-{beta}: Recent Lessons from in Vivo Studies Mol. Endocrinol., January 1, 2007; 21(1): 1 - 13. [Abstract] [Full Text] [PDF]

				K. A. Johnson The SERM of My Dreams. J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3754 - 3756. [Full Text] [PDF]

				J. L. Turgeon, M. C. Carr, P. M. Maki, M. E. Mendelsohn, and P. M. Wise Complex Actions of Sex Steroids in Adipose Tissue, the Cardiovascular System, and Brain: Insights from Basic Science and Clinical Studies Endocr. Rev., October 1, 2006; 27(6): 575 - 605. [Abstract] [Full Text] [PDF]

				R. W. Hsieh, S. S. Rajan, S. K. Sharma, Y. Guo, E. R. DeSombre, M. Mrksich, and G. L. Greene Identification of Ligands with Bicyclic Scaffolds Provides Insights into Mechanisms of Estrogen Receptor Subtype Selectivity J. Biol. Chem., June 30, 2006; 281(26): 17909 - 17919. [Abstract] [Full Text] [PDF]

				T. R. Pak, W. C. J. Chung, J. L. Roberts, and R. J. Handa Ligand-Independent Effects of Estrogen Receptor {beta} on Mouse Gonadotropin-Releasing Hormone Promoter Activity Endocrinology, April 1, 2006; 147(4): 1924 - 1931. [Abstract] [Full Text] [PDF]

				J Christoffel, G Rimoldi, and W Wuttke Effects of 8-prenylnaringenin on the hypothalamo-pituitary-uterine axis in rats after 3-month treatment. J. Endocrinol., March 1, 2006; 188(3): 397 - 405. [Abstract] [Full Text] [PDF]

				M. T. Follettie, M. Pinard, J. C. Keith Jr., L. Wang, D. Chelsky, C. Hayward, P. Kearney, P. Thibault, E. Paramithiotis, A. J. Dorner, et al. Organ Messenger Ribonucleic Acid and Plasma Proteome Changes in the Adjuvant-Induced Arthritis Model: Responses to Disease Induction and Therapy with the Estrogen Receptor-{beta} Selective Agonist ERB-041 Endocrinology, February 1, 2006; 147(2): 714 - 723. [Abstract] [Full Text] [PDF]

				O. Imamov, G.-J. Shim, M. Warner, and J.-A. Gustafsson Estrogen Receptor beta in Health and Disease Biol Reprod, November 1, 2005; 73(5): 866 - 871. [Abstract] [Full Text] [PDF]

				T. Pelzer, V. Jazbutyte, K. Hu, S. Segerer, M. Nahrendorf, P. Nordbeck, A. W. Bonz, J. Muck, K.-H. Fritzemeier, C. Hegele-Hartung, et al. The estrogen receptor-{alpha} agonist 16{alpha}-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats Cardiovasc Res, September 1, 2005; 67(4): 604 - 612. [Abstract] [Full Text] [PDF]

				K. F. Koehler, L. A. Helguero, L.-A. Haldosen, M. Warner, and J.-A. Gustafsson Reflections on the Discovery and Significance of Estrogen Receptor {beta} Endocr. Rev., May 1, 2005; 26(3): 465 - 478. [Abstract] [Full Text] [PDF]